PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17989609-5	2007	RESULTS: Sirolimus inhibited low-density lipoprotein (LDL) receptor (LDLr)-mediated cholesterol ester accumulation induced by interleukin-1beta in HepG2 cells.	Sirolimus	9-18	low density lipoprotein receptor	Homo sapiens	29-67	
24713582-2	2014	Recently, it was shown that rapamycin decreases hepatic LDL receptor (LDL-R) expression, which likely contributes to hypercholesterolemia.	Sirolimus	28-37	low density lipoprotein receptor	Homo sapiens	56-68	
24713582-2	2014	Recently, it was shown that rapamycin decreases hepatic LDL receptor (LDL-R) expression, which likely contributes to hypercholesterolemia.	Sirolimus	28-37	low density lipoprotein receptor	Homo sapiens	70-75	
19180880-3	2008	The effects of rapamycin on interleukin-1 beta (IL-1 beta)-induced mRNA and protein changes of low-density lipoprotein receptor (LDLR) and ATP-binding cassette transporter A1 (ABCA1) were assayed by quantitative real-time PCR and Western blot.	Sirolimus	15-24	low density lipoprotein receptor	Homo sapiens	95-127	
19180880-3	2008	The effects of rapamycin on interleukin-1 beta (IL-1 beta)-induced mRNA and protein changes of low-density lipoprotein receptor (LDLR) and ATP-binding cassette transporter A1 (ABCA1) were assayed by quantitative real-time PCR and Western blot.	Sirolimus	15-24	low density lipoprotein receptor	Homo sapiens	129-133	
19180880-6	2008	Rapamycin dose-dependently suppressed the increased expression of LDLR induced by IL-1 beta and up-regulated the suppressed expression of ABCA1 caused by IL-1 beta.	Sirolimus	0-9	low density lipoprotein receptor	Homo sapiens	66-70	
18602894-0	2008	Rapamycin down-regulates LDL-receptor expression independently of SREBP-2.	Sirolimus	0-9	low density lipoprotein receptor	Homo sapiens	25-37	
18602894-7	2008	However, LDL-receptor gene expression was decreased by rapamycin, suggesting that this may contribute to the hyperlipidaemia observed in rapamycin-treated patients.	Sirolimus	55-64	low density lipoprotein receptor	Homo sapiens	9-21	
18602894-7	2008	However, LDL-receptor gene expression was decreased by rapamycin, suggesting that this may contribute to the hyperlipidaemia observed in rapamycin-treated patients.	Sirolimus	137-146	low density lipoprotein receptor	Homo sapiens	9-21	
18602894-8	2008	Rapamycin did not affect mRNA stability, so the decrease in LDL-receptor gene expression is likely to be occurring at the transcriptional level, although independently of SREBP-2.	Sirolimus	0-9	low density lipoprotein receptor	Homo sapiens	60-72	
17989609-5	2007	RESULTS: Sirolimus inhibited low-density lipoprotein (LDL) receptor (LDLr)-mediated cholesterol ester accumulation induced by interleukin-1beta in HepG2 cells.	Sirolimus	9-18	low density lipoprotein receptor	Homo sapiens	69-73	
17989609-7	2007	Using confocal microscopy, we demonstrated that sirolimus reduced translocation of SCAP-SREBP2 complex from endoplasmic reticulum to Golgi for activation, thereby inhibiting LDLr gene transcription.	Sirolimus	48-57	low density lipoprotein receptor	Homo sapiens	174-178	
17989609-11	2007	CONCLUSIONS: This study demonstrates that the increase of LDL cholesterol by sirolimus is partly due to the reduction of LDLr on hepatocytes.	Sirolimus	77-86	low density lipoprotein receptor	Homo sapiens	121-125